(Alliance News) - Oxford Biomedica PLC on Tuesday said the fourth GMP manufacturing suite at its new Oxbox manufacturing facility has been approved by a UK regulator.
The gene and cell therapy company said the manufacturing suite, located at its new commercial manufacturing centre in Oxford, was issued a Certificate of GMP compliance by the UK Medicines & Healthcare Products Regulatory Agency.
The first phase of Oxbox consists of six GMP manufacturing suites plus warehousing, support laboratories and cold chain facilities. Construction and commissioning of this phase completed in 2019.
The newly approved fourth suite, along with the previously approved third suite, will be dedicated to manufacturing a Covid-19 viral vector vaccine candidate and equipment for both has been provided by the Vaccine Manufacturing & Innovation Centre.
Chief Executive John Dawson said: "We are delighted that we now have all four GMP suites in Oxbox operational, more than doubling our manufacturing capacity from 2019. I want to personally thank all of those at Oxford Biomedica who have worked tirelessly to bring these suites on-line so quickly to enable the manufacturing at scale of the vaccine candidate. We also want to thank VMIC for their support with the rapid deployment of their equipment to our site, which has played a key part in achieving the operational readiness of these suites in this short timeframe."
Shares in Oxford Biomedica were up 0.7% at 850.79 pence in London on Tuesday morning.
By Anna Farley; annafarley@alliancenews.com
Copyright 2020 Alliance News Limited. All Rights Reserved.
Oxford Biomedica (OXB)